Evidence map›Paper›PMID 39981976›Full record

ArticleCNS neuroscience & therapeutics2025

Targeting LncRNA-Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief.

Xiuying He, David H Mauki, Xiaoming Zhao, Songyu Dai, Huisi Yang, Yuexiang Zheng, Qingjie Xia, Rurong Wang, Tinghua Wang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xiuying HeDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0001-6320-9766
David H MaukiDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Xiaoming ZhaoDepartment of Basic Medicine, Medical School, Kunming University of Science and Technology, Kunming, China.
Songyu DaiDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Huisi YangSchool of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, China.
Yuexiang ZhengSchool of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, China.
Qingjie XiaInstitute of Neurological Disease, West China Hospital, Sichuan University, Chengdu, China.
Rurong WangDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Tinghua WangDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-2012-8936

Funding

Key Research and Development Program of Sichuan Science and Technology Agency 2020YFS0043National Natural Science Foundation of China 81471268Natural Science Foundation of Sichuan Province of China 2023NSFSC1567Sichuan University Innovation Research Project 2023SCUH0033
6 · The paper itself

Abstract

aimsNeuropathic pain (NP) is a debilitating condition characterized by chronic pain resulting from nerve damage or lesion. Despite the ongoing efforts of clinically defining NP, its distinctive mechanisms that lead to various NP phenotypes remain unresolved.

methodsUsing a spared nerve injury (SNI) model, we investigated the mechanisms underlying the development of NP caused by injury in the peripheral nerves. With CRISPR-Cas9-mediated knockout and virus-mediated overexpression strategies, we investigated the role of LncRNA Vof16 (abbreviated as Vof16) during SNI-induced NP.

resultsOur results revealed that SNI led to the downregulation of Vof16 expression in spinal dorsal horn (SDH) of lumbar enlargement. This was evidently confirmed when we disrupted the expression of Vof16 in SNI rats of which we observed exacerbation of hyperalgesia; while overexpressing it alleviated the pain.

conclusionOur findings suggest that Vof16 plays a crucial role in maintaining normal sensory function in healthy states and a protective shield against NP following peripheral nerve injury. We therefore propose Vof16 as a new therapeutic target for alleviating NP.

Indexed as

NeuralgiaRNA, Long NoncodingAnimalsCRISPR-Cas SystemsDisease Models, AnimalHyperalgesiaMalePeripheral Nerve InjuriesRatsRats, Sprague-DawleySpinal Cord Dorsal HornRNA, Long NoncodinghyperalgesiaLncRNA‐Vof16neuropathic painperipheral nerve injuryspared nerve injury

Identifiers

PMID39981976
PMCPMC11843576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.